Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma

Cancer Gene Therapy

Volumn 8, Issue 5, 2001, Pages 361-370

  Wen, Xiao Yan ^a   Mandelbaum, Saul ^a   Li, Zhi H ^b   Hitt, Mary ^b   Graham, Frank L ^b   Hawley, Teresa S ^c   Hawley, Robert G ^c   Stewart, A Keith ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HOLLAND LABORATORY   (United States)

Author keywords

Adenovirus and gene therapy; CD80; IL 12; Immunotherapy; Myeloma

Indexed keywords

B7 ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 12; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENCEPHALOMYOCARDITIS VIRUS; FOOT AND MOUTH DISEASE VIRUS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MULTIPLE MYELOMA; MYELOMA; PRIORITY JOURNAL; RETROVIRUS;

ADENOVIRIDAE; ANTIGENS, CD80; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; DNA, COMPLEMENTARY; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; NEOPLASMS; RETROVIRIDAE; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0034920504     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700321     Document Type: Article

References (52)

1. Cancer gene therapy: Connecting basic research with clinical inquiry
2. Cancer vaccines
3. Cancer vaccines
4. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony-stimulating factor stimulates potent, specific and long-lasting antitumor immunity
5. Adenovector mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a Phase 1 trial
6. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
7. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma
8. MHC-dependent antigen processing and peptide presentation: Providing ligands for T-lymphocyte activation
9. B70 antigen is a second ligand for CTLA-4 and CD28
10. Co-stimulation of T lymphocytes: The role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy
11. The role of CD28 receptor during T-cell responses to antigen
12. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 co-stimulation
13. A reassessment of the role of B7-1 expression in tumor rejection
14. Interleukin 12: Basic principles and clinical applications
15. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells
16. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12
17. The antitumor effects of IL-12 involve enhanced IFN-gamma production by antitumor T cells, their accumulation to tumor sites and in situ IFN-gamma production
18. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors
19. Enhanced immunogenicity of B-cell lymphoma genetically engineered to express both B7-1 and interleukin-12
20. Co-expression of B7-1 with interleukin-12 enhances vaccine-induced antitumor immunity in experimental myeloma
21. Interleukin-12 and B7-1 co-stimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression
22. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
23. Donor leukocyte infusions are effective in relapsed myeloma after allogeneic bone marrow transplantation
24. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor
25. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
26. Tumor rejection antigen 1 (GRP94) expression is induced by CD40 ligand activation of multiple myeloma cells and mediates allogeneic T-cell reactivity
27. A single nucleotide substitution in the internal ribosome entry site of foot-and-mouth disease virus leads to enhanced cap-independent translation in vivo
28. Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: Implications for immune gene therapy
29. Retroviral vectors for production of interleukin-12 in the bone marrow to induce a graft-versus-leukemia effect
30. Versatile retroviral vectors for potential use in gene therapy
31. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus
32. Human adenovirus vectors for gene transfer into mammalian cells
33. B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (AdB7) expression vector
34. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
35. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active interleukin 12
36. Expression of co-stimulatory molecules CD80 and/or CD86 by a Kaposi's sarcoma tumor cell line induces differential T-cell activation and proliferation
37. Pivotal role of the B7:CD28 pathway in transplantation, tolerance and tumor immunity
38. A reassessment of the role of B7-1 expression in tumor rejection
39. Tumor immunogenicity determines the effect of B7 co-stimulation on T-cell-mediated tumor immunity
40. IL-12 receptor: II. Distribution and regulation of receptor expression
41. Role of IL-12 as an antitumor agent: Current status and future directions
42. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10
43. Construction and characterization of a triple recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen
44. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors
45. Amount of interleukin 12 available at the tumor site is critical for tumor regression
46. Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multi-drug resistant myeloma cells: The role of cytotoxic T lymphocytes
47. Interleukin 2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma
48. Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells
49. Gene transfer of co-stimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T-cell response
50. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
51. Idiotypic immunization combined with granulocyte macrophage colony-stimulating factor in myeloma patients-induced type I, major histocompatibility complex restricted CD8- and CD4-specific T-cell responses